Diarrhea News and Research

Latest Diarrhea News and Research

Three winners announced for biomedical engineering design competition in DEBUT challenge

...

13 Aug 2013

Patients with IBS-D treated with eluxadoline achieve better clinical response

Patients with diarrhea-predominant irritable bowel syndrome, or IBS-D, treated with eluxadoline achieved better clinical response and experienced more symptom improvement than those using placebo, according to a recent study in Gastroenterology, the official journal of the American Gastroenterological Association. Eluxadoline, which is currently in phase 3 trials, is under development as a potential treatment for IBS-D.

13 Aug 2013

Harvard University receives grant to use organs-on-chips device to test human response to radiation

A team at the Wyss Institute for Biologically Inspired Engineering at Harvard University has received a $5.6 million grant award from the United States Food and Drug Administration (FDA) to use its Organs-on-Chips technology for a novel application of keen interest to national security and health officials: to test human physiological responses to radiation, and to evaluate drugs designed to counter those effects.

13 Aug 2013

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Romark Laboratories announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States.

7 Aug 2013

Celiac disease patients with persistent intestine damage are at higher risk of lymphoma

Patients with celiac disease who had persistent intestine damage (identified with repeat biopsy) had a higher risk of lymphoma than patients whose intestines healed, according to findings published in the August 6, 2013, issue of Annals of Internal Medicine.

6 Aug 2013

Cyp11a1 enzyme is a potential target for treatment of deadly food allergy, say researchers

Researchers at National Jewish Health have identified an enzyme that is essential to the allergic reaction to peanuts. Blocking the enzyme's activity in sensitized mice prevented diarrhea and inflammation, and reduced levels of several proteins associated with allergies.

2 Aug 2013

Viropharma announces financial results for second quarter of 2013

VIROPHARMA INCORPORATED (Nasdaq: VPHM) today announced financial results for the second quarter of 2013. Net sales were $104 million for the second quarter ended June 30, 2013 as compared to $95 million in the comparative period of 2012.

1 Aug 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Afatinib has a novel mode of action and data has shown that it offers a clinical benefit to patients with a specific type of lung cancer, which we are further investigating in the extensive LUX-Lung clinical trial programme.

1 Aug 2013

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Nektar Therapeutics (NASDAQ: NKTR) today announced that enrollment is complete in the pivotal clinical study of etirinotecan pegol (NKTR-102) in patients with metastatic breast cancer.

31 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) provide the first proof of concept data showing that a monoclonal antibody can neutralize human norovirus. This research, which could one day lead to effective therapies against the virus, was published online ahead of print in the Journal of Virology.

25 Jul 2013

Researchers develop PEDV rapid diagnostic test

Mere months after porcine epidemic diarrhea virus (PEDV) was first confirmed in the United States swine population, University of Minnesota researchers have developed a PEDV rapid diagnostic test.

24 Jul 2013

Animal model of human norovirus lays groundwork for developing antiviral drug treatment

An animal model of the human norovirus created at the University of Michigan Health System lays the groundwork for understanding the biology of the pesky virus and developing antiviral drug treatment.

23 Jul 2013

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab induction.

20 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

UCI-led study point to new approach for treating foodborne illnesses

UC Irvine microbiologists have learned how a probiotic bacterium used to treat irritable bowel syndrome can soothe gut bacterial infections caused by Salmonella, paving the way for potential relief from foodborne illnesses that affect millions of people annually.

18 Jul 2013

Social media and DNA fingerprinting played important role in alerting strep outbreak

Facebook posts helped alert public health officials to a strep throat outbreak among a high school dance team in 2012, and DNA fingerprinting led investigators to pasta prepared by a previously ill parent as the likely source.

18 Jul 2013

Diarrhea News and Research

Latest Diarrhea News and Research

Three winners announced for biomedical engineering design competition in DEBUT challenge

Patients with IBS-D treated with eluxadoline achieve better clinical response

Harvard University receives grant to use organs-on-chips device to test human response to radiation

Lupin acquires exclusive license to promote, distribute Romark's Alinia for Oral Suspension in US

Celiac disease patients with persistent intestine damage are at higher risk of lymphoma

Cyp11a1 enzyme is a potential target for treatment of deadly food allergy, say researchers

Viropharma announces financial results for second quarter of 2013

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Nektar completes enrollment in NKTR-102 BEACON trial in patients with metastatic breast cancer

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

NIAID researchers discover monoclonal antibody can neutralize human norovirus

Researchers develop PEDV rapid diagnostic test

Animal model of human norovirus lays groundwork for developing antiviral drug treatment

FDA approves Astellas' ASTAGRAF XL for prophylaxis of organ rejection in kidney transplant patients

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

UCI-led study point to new approach for treating foodborne illnesses

Social media and DNA fingerprinting played important role in alerting strep outbreak

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in